In ER+ breast cancer, Notch4 increases breast cancer stem cell activation and endocrine therapy resistance, proposing that Notch4 inhibition will overcome endocrine therapy resistance and decrease recurrence in ER+ breast cancer [16, 17]. This evidence concerns the gene NOTCH4 and breast carcinoma.